Oncoinvent (Norway)
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma.
Basic Information
- Category: business
- Founded: 2010
- Website: http://oncoinvent.com/
Documented Facts
- Email: oncoinvent@oncoinvent.com (No linked source recorded for this statement.)
- Founded: 2010 (No linked source recorded for this statement.)
- Website: http://oncoinvent.com/ (No linked source recorded for this statement.)
- CEO: of Arxx Therapeutics (No linked source recorded for this statement.)
Evidence and Sources
- Oncoinvent (Norway) — Official Site (official)
- Oncoinvent (Norway) on linkedin (social)
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Oncoinvent (Norway).
- Canonical profile: https://brandsource.ai/brands/oncoinvent-norway
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/oncoinvent-norway/json-ld
- Citation profile API: https://brandsource.ai/api/brands/oncoinvent-norway/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (90/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-22
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma.
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 1 supporting source linked.
- 4 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.